Procalcitonin guided reduction of the duration of antibiotic therapy in Community Acquired Pneumonia
- Conditions
- Community Acquired Pneumonia (CAP)RespiratoryPneumonia
- Registration Number
- ISRCTN04176397
- Lead Sponsor
- niversity Hospital Basel (Switzerland)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 250
The criterion for inclusion in the study was a suspected CAP as the main diagnosis. This was defined as presence of a new infiltrate on chest X-ray accompanied by one or several acquired respiratory symptoms and signs:
1. Cough
2. Sputum production
3. Dyspnoea
4. Fever over 38.0°C
5. Auscultatory findings of abnormal breath sounds and rales
6. Leukocytosis more than 10 x 10^9 cells/L or leukopenia less than 4 x 10^9 cells/L in the absence of a hospital stay within 14 days before admission
1. Cystic fibrosis or active tuberculosis
2. Immunocompromised patients, i.e. patients infected with Human Immunodeficiency Virus (HIV) infection and a CD4 count below 200
3. Neutropenic patients with a neutrophil count less than 500 x 10^9/ml
4. Under chemotherapy with neutrophils 500 - 1000 x 10^9/ml with an expected decrease to values less than 500 x 10^9/ml
5. Immunosuppressive therapy after bone marrow or solid organ transplantation
6. Nosocomial pneumonia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total antibiotic use, recorded on days 4, 6, and 8 and at follow-up after 6 weeks.
- Secondary Outcome Measures
Name Time Method Measures of laboratory and clinical outcomes, recorded on days 4, 6, and 8 and at follow-up after 6 weeks.